Literature DB >> 8158881

Hypercholesterolemia--a determinant of renal function loss and deaths in IDDM patients with nephropathy.

A S Krolewski1, J H Warram, A R Christlieb.   

Abstract

The development of kidney disease in diabetes mellitus can be viewed as a two-stage process: (1) the development of proteinuria, and (2) its progression to chronic renal failure. Determinants of the latter were examined in 439 IDDM patients who had nephropathy and participated in the Diabetic Retinopathy Study. Using serum creatinine levels obtained during the follow-up period to assess the rate of loss of renal function, we found that only one-third of these patients experienced a rapid loss of function, while the others had slowly declining or unchanging renal function despite the presence of proteinuria and severe diabetic retinopathy. Among the many baseline variables examined, only elevated cholesterol and elevated systemic blood pressure were predictors of a rapid loss of renal function. Patients with this rapid loss of renal function also had the highest risk of death due to cardiovascular causes, as well as all causes. Once again, hypercholesterolemia was the major predictor of these deaths. In conclusion, efforts should be undertaken early to identify patients who are rapidly losing renal function so that interventions to modify systemic blood pressure and hypercholesterolemia may prevent or postpone the development of renal failure and death in patients with IDDM.

Entities:  

Mesh:

Year:  1994        PMID: 8158881

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  18 in total

Review 1.  Is it possible to predict diabetic kidney disease?

Authors:  S M Thomas; G C Viberti
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

Review 2.  Management of diabetic nephropathy.

Authors:  L Foggensteiner; S Mulroy; J Firth
Journal:  J R Soc Med       Date:  2001-05       Impact factor: 5.344

Review 3.  Lipids and diabetic nephropathy.

Authors:  Rey F Rosario; Sharma Prabhakar
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

4.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

5.  Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria.

Authors:  Carol Forsblom; Valma Harjutsalo; Lena M Thorn; Johan Wadén; Nina Tolonen; Markku Saraheimo; Daniel Gordin; John L Moran; Merlin C Thomas; Per-Henrik Groop
Journal:  J Am Soc Nephrol       Date:  2011-02-18       Impact factor: 10.121

Review 6.  Lipids and diabetic renal disease.

Authors:  Mark E Cooper; Karin A M Jandeleit-Dahm
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

7.  Biochemical effects of irbesartan in experimental diabetic nephropathy.

Authors:  Richa Vaishya; J Singh; Harbans Lal
Journal:  Indian J Pharmacol       Date:  2009-12       Impact factor: 1.200

8.  Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model.

Authors:  Xiaoxin X Wang; Tao Jiang; Yan Shen; Yupanqui Caldas; Shinobu Miyazaki-Anzai; Hannah Santamaria; Cydney Urbanek; Nathaniel Solis; Pnina Scherzer; Linda Lewis; Frank J Gonzalez; Luciano Adorini; Mark Pruzanski; Jeffrey B Kopp; Jill W Verlander; Moshe Levi
Journal:  Diabetes       Date:  2010-08-10       Impact factor: 9.461

9.  Familial factors determine the development of diabetic nephropathy in patients with IDDM.

Authors:  M Quinn; M C Angelico; J H Warram; A S Krolewski
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

10.  Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes.

Authors:  Siwei Zhang; Huali Xu; Xiaofeng Yu; Yi Wu; Dayun Sui
Journal:  Exp Ther Med       Date:  2017-05-18       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.